Use of real-world evidence in meta-analyses and cost-effectiveness models

被引:6
|
作者
Bowrin, Kevin [1 ]
Briere, Jean-Baptiste [2 ]
Levy, Pierre [3 ]
Toumi, Mondher [4 ]
Millier, Aurelie [5 ]
机构
[1] Bayer Plc, 400 South Oak Way, Reading RG2 6AD, Berks, England
[2] Bayer AG, Berlin, Germany
[3] PSL Res Univ, Univ Paris Dauphine, LEDa LEGOS, Pl Marechal Lattre Tassigny, Paris, France
[4] Aix Marseille Univ, Ctr Etud & Rech Serv Sante & Qualite Vie, Marseille, France
[5] Creat Ceut, Paris, France
关键词
Anticoagulants; atrial fibrillation; meta-analysis; cost-effectiveness; real-world evidence; stroke prevention; HEALTH TECHNOLOGY-ASSESSMENT; CARE DECISION-MAKING; ATRIAL-FIBRILLATION; METHODOLOGICAL QUALITY; ECONOMIC EVALUATIONS; ORAL ANTICOAGULANTS; RIVAROXABAN; STROKE; RISK; BIAS;
D O I
10.1080/13696998.2020.1792917
中图分类号
F [经济];
学科分类号
02 ;
摘要
Real-world evidence (RWE) provides external validity, supplementing and enhancing the randomized controlled trial data with valuable information on patient behaviors and outcomes, turning efficacy and safety results into real-world effectiveness and risks, but the use of RWE is associated with challenges. The objectives of this communication were to (1) summarize all guidance on how to conduct an RWE meta-analysis (MA) and how to develop an RWE cost-effectiveness model, (2) to describe our experience, challenges faced and solutions identified, (3) to provide recommendations on how to conduct such analyses. No formal guidelines on how to conduct an RWE MA or to develop an RWE cost-effectiveness model were identified. Using the context of non-vitamin K antagonist oral anticoagulants in stroke prevention in atrial fibrillation, we conducted an RWE MA, after having identified sources of uncertainty. We then implemented the results in an RWE cost-effectiveness model, defined as a model where all inputs come from RWE, including all parameters related to treatment effect. Based on challenges faced, our first recommendation relates to the necessity of conducting sensitivity analyses, either based on clinical or methodological considerations. Our second recommendation is the need for extensive collaboration with a wide range of experts, during the development of the analyses protocols, the implementation of the analyses and the interpretation of the results. RWE may address a number of gaps related to the treatment effect, and RWE economic evaluations for the treatment effect can provide extremely valuable insights into real-world economic value of interventions. As the increased recognition of the value of RWE could influence health technology assessment decision, and current practices, this communication supports the urgent need of more formal guidelines.
引用
收藏
页码:1053 / 1060
页数:8
相关论文
共 50 条
  • [31] A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation
    Hill, Nathan R.
    Sandler, Belinda
    Bergrath, Evelien
    Milenkovic, Dusan
    Ashaye, Ajibade O.
    Farooqui, Usman
    Cohen, Alexander T.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26
  • [32] Effectiveness and Cost-Effectiveness of eHealth Interventions in Somatic Diseases: A Systematic Review of Systematic Reviews and Meta-Analyses
    Elbert, Niels J.
    van Os-Medendorp, Harmieke
    van Renselaar, Wilco
    Ekeland, Anne G.
    Hakkaart-van Roijen, Leona
    Raat, Hein
    Nijsten, Tamar E. C.
    Pasmans, Suzanne G. M. A.
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2014, 16 (04) : 182 - 204
  • [33] REAL-WORLD EVIDENCE ON THE RISE: EVALUATING THE USE OF REAL-WORLD EVIDENCE IN ICER ASSESSMENTS OF COMPARATIVE CLINICAL EFFECTIVENESS
    Drane, E.
    Upton, E.
    Morten, P.
    Walker, E.
    VALUE IN HEALTH, 2019, 22 : S316 - S316
  • [34] Statin Cost-Effectiveness Comparisons Using Real-World Effectiveness Data: Formulary Implications
    Ohsfeldt, Robert L.
    Gandhi, Sanjay K.
    Fox, Kathleen M.
    McKenney, James M.
    VALUE IN HEALTH, 2008, 11 (07) : 1061 - 1069
  • [35] Cost-effectiveness of an Evidence-Based Childhood Asthma Intervention in Real-World Primary Care Settings
    Dor, Avi
    Luo, Qian
    Gerstein, Maya Tuchman
    Malveaux, Floyd
    Mitchell, Herman
    Markus, Anne Rossier
    JOURNAL OF AMBULATORY CARE MANAGEMENT, 2018, 41 (03): : 213 - 224
  • [36] Clinical efficacy and cost-effectiveness of metformin in different patient populations: A narrative review of real-world evidence
    Solini, Anna
    Trico, Domenico
    DIABETES OBESITY & METABOLISM, 2024, 26 : 20 - 30
  • [37] META-ANALYSES USING REAL-WORLD DATA: A SYSTEMATIC LITERATURE REVIEW OF EXISTING RECOMMENDATIONS
    Briere, J.
    Bowrin, K.
    Millier, A.
    Toumi, M.
    Taieb, V
    VALUE IN HEALTH, 2018, 21 : S398 - S398
  • [38] Comparison of effectiveness of premixed insulin with long-acting insulin in diabetes: evidence from real-world cohort studies—systematic review and meta-analyses
    Ziping Ye
    Qian Xin
    Xiaotong Jiang
    Lihua Sun
    International Journal of Diabetes in Developing Countries, 2018, 38 : 366 - 374
  • [39] Trial sequential analysis in meta-analyses: A clinically oriented approach with real-world example
    Chan, Jeffrey Shi Kai
    Harky, Amer
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 162 (01): : 167 - 173
  • [40] Real-world eligibility and cost-effectiveness analysis for empagliflozin in patients with heart failure
    Kim, E. S.
    Park, S. K.
    Youn, J. C.
    EUROPEAN HEART JOURNAL, 2022, 43 : 972 - 972